Balance test results. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Mechanism analysis results. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Endogenous test results. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Heterogeneity analysis results. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Robustness test results. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Baseline results of the impact of RLM on HWSW. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

The influencing factors of RLM. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Variable definitions and basic statistics. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

Average and marginal effects of RLM on HWSW. by Yi Yu (28902)

“…Specifically, with every 1% increase in RLM, the likelihood of rural residents’ HWSW will decrease by 3.5%. This effect remains significant after a series of robustness checks. …”

TAD analysis for <i>Sox10.</i> by Hongjoo An (21703199)

Patient selection flowchart. by Aihong Zheng (20571034)

Table of Mann-Whitney test results on lectin microarray. by Yiying Zhang (198443)

Niche overlap within shelf communities. by Nathan D. McTigue (10706460)

Niche overlap within fjord communities. by Nathan D. McTigue (10706460)

Activity monitoring of wild-type and <i>rho-l</i> mutant strains of <i>Aedes albopictus</i>. by Si Yu Zhao (19544793)

FoxO3a-dependent mechanism of miR-150-5p in regulating pyroptosis in ox-LDL-stimulated RAW264.7 macrophages. (A-E) FoxO3a and ARC expression analyzed by (A-C) RT-qPCR and (D-E) Wes... by Ping-yu Cai (12389929)

Comparison of the shadow index of blindfolded compound eyes with wild-type gravid mosquitoes. by Si Yu Zhao (19544793)

Baseline characteristics. by A. H. Ayesha Lavell (16734002)

“…No differences were found regarding patient care roles, prior SARS-CoV-2 infection, years of work experience, or hospital workdays per week. Mental health significantly declined during the COVID-19 pandemic, after which mental health symptoms returned to baseline as the burden of COVID-19 patients decreased and public measures were lifted. …”

De-identified participant survey data. by A. H. Ayesha Lavell (16734002)

“…No differences were found regarding patient care roles, prior SARS-CoV-2 infection, years of work experience, or hospital workdays per week. Mental health significantly declined during the COVID-19 pandemic, after which mental health symptoms returned to baseline as the burden of COVID-19 patients decreased and public measures were lifted. …”

Raw data underlying figures 1–7. by Alejandra Barrera-Rosales (21656278)

“…In M0 and M2 macrophages, the SMPs induced a mixed secretion of cytokines such as TNF-α, IL-10, and IL-12p40, and a significant decrease of TGF-β1. Recognizing the effects triggered by these SMPs on these cells of the innate immune system will allow us to propose rational uses for these SMPs in prophylactic and therapeutic vaccines intended to be used by the nasal/pulmonary route.…”